A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
- Conditions
- Acute lower respiratory infectionTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- CTIS2022-502022-41-00
- Lead Sponsor
- Moderna Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 458
The participant is male or female, 8 months to <24 months (Part A) or 5 months to <8 months (Part B) of age at the time of randomization (Day 1/Baseline visit), who is in good general health, in the opinion of the Investigator, based on review of medical history and screening physical examination. Common benign infant conditions (eg, mild to moderate GERD or atopic dermatitis not interfering with injection-site assessment) are allowed., In the Investigator’s opinion, the parent(s)/LAR(s) understand and are willing and physically able to comply with protocol-mandated follow up, including all procedures, and provide written informed consent., The participant is growing normally for age in the opinion of the site clinician in the months prior to enrollment., The participant was born at full-term (=37 weeks gestation) with a minimum birth weight of 2.5 kg., Participant’s parent(s)/LAR(s) must have access to a consistent means of contact either by telephone contact or email/computer.
Has a known history of symptomatic RSV or hMPV infection (Part A: within 3 months; Part B: since birth) prior to administration of the first dose of IP or has a known close contact with anyone with laboratory-confirmed RSV or hMPV infection within 14 days prior to administration of the first dose of IP (Part A and Part B)., Is an immediate family member, or household contact, of an employee of the study site or the Sponsor or someone otherwise directly involved with the conduct of the study. As applicable, family members/household contacts of employees of the larger institution or affiliated private practice not part of the study site may be enrolled if the Investigator does not have any influence over their employment status., A child who has been placed under the control or protection of an agency, organization, institution, or entity by the courts, the government, or a government body acting in accordance with powers conferred on them by laws and regulation (eg, foster care). This does not include a child who is adopted or has an appointed legal guardian., Is acutely ill or febrile 24 hours prior to or at the Screening Visit. Fever is defined as a body temperature =38.0°C/ =100.4°F. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Participants who are afebrile with minor illnesses can be enrolled at the discretion of the Investigator., Has previously been administered an investigational or approved vaccine for prevention of RSV or hMPV infection or if the participant’s mother received an investigational or approved vaccine for the prevention of RSV or hMPV infection during pregnancy., Has received investigational or approved agents for prophylaxis against RSV or hMPV (eg, monoclonal antibodies), or is intending to receive these during the course of the study., Has a known hypersensitivity to a component of the vaccine or its excipients. Hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mRNA vaccine or any of its components (including polyethylene glycol or immediate allergic reaction of any severity to polysorbate)., Has a medical condition that, according to the Investigator’s judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results., Has a history of diagnosis or condition that, in the judgment of the Investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: a. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination. b. Serious chronic illness c. Major congenital defects d. History of any neurological disorders or seizures e. History of or current autoimmune disease f. History of recurrent wheezing (wheezing should have been verified on auscultation by a doctor) g. History of chronic cough (8 weeks or more duration) h. Previous hospitalization for respiratory illnesses i. History of thrombocytopenia j. History of anemia k. Neurological complications following any prior vaccination l. Born to a mother known or suspected to be HIV positive or Hepatitis C positive (no laboratory testing required) m. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required) n. Chronic he
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To evaluate the safety and reactogenicity of study injections;Secondary Objective: To evaluate the occurrence of clinical RSV or hMPV infections in study participants., To evaluate the antibody response to each study injection., To characterize cellular immunogenicity in a subset of participants.;Primary end point(s): Solicited local and systemic ARs through 7 days after each injection., Unsolicited AEs through 28 days after each injection., MAAEs from Day 1 to EoS., AESIs from Day 1 to EoS., SAEs from Day 1 to EoS., AEs leading to discontinuation from Day 1 to EoS.
- Secondary Outcome Measures
Name Time Method Secondary end point(s):Number and percentage of participants with RTI, LRTI, severe LRTI, very severe LRTI, and hospitalizations associated with RSV or hMPV from Day 1 through EoS.;Secondary end point(s):GMT of serum RSV and hMPV neutralizing antibody across prespecified study timepoints.;Secondary end point(s):GMC of serum RSV F and hMPV F–binding antibody across prespecified study timepoints.;Secondary end point(s):GMFR of postbaseline/baseline neutralizing antibody titers and binding antibody concentrations across prespecified study timepoints.;Secondary end point(s):Frequency, magnitude, and/or phenotype of vaccine-specific T-cell responses measured by flow cytometry or other methods.